Searchable abstracts of presentations at key conferences in endocrinology

ea0035p495 | Diabetes therapy | ECE2014

Efficacy of acarbose in different geographical regions of the world: analysis of a real-life database

Kalra Sanjay , Soegondo Sidartawan , Schnell Oliver , Sheu Wayne H-H , Grzeszczak Wladyslaw , Watada Hirotaka , Yamamoto Noriyuki , Weng Jianping

Introduction: Although alpha-glucosidase inhibitors (aGIs), including acarbose, are recommended in several international guidelines, they are not widely used worldwide due to a perception that they are less effective in Caucasians than Asians. A study was undertaken to investigate whether differences between ethnicity/region populations exist.Methods/design: We pooled data from 10 non-interventional and post-marketing studies from 21 countries, provinces...

ea0026p34 | Adrenal cortex | ECE2011

Norwegian patients with congenital adrenal hyperplasia have a high frequency of adrenal myelolipomas and adrenal hypoplasia, and testicular adrenal rest tumours was only detected in men with the saltwasting form

Nermoen I N , Rorvik J R , Holmedal S H H , Hykkerud D L H , Fougner K J , Svartberg J S , Husebye E S H , Lovas K L

Background: Increased frequencies of adrenal tumours and testicular adrenal rest tumours (TART) have been reported in congenital adrenal hyperplasia (CAH).Objective: To investigate the frequency of adrenal abnormalities and TART in an unselected adult population of CAH due to 21-hydroxylase deficiency (21-OH) and whether adrenal and testicular pathology correlate with disease categories, current hormone levels and treatment.Patient...

ea0026p455 | Thyroid cancer | ECE2011

The effects of four different tyrosine kinase inhibitors on medullary and papillary thyroid cancer cells

Verbeek H H G , Alves M M , deGroot J W B , Osinga J , Plukker J T M , Links T P , Hofstra R M W

Introduction: Medullary and papillary thyroid carcinoma (MTC and PTC) are two types of thyroid cancer that can originate from activating mutations or rearrangements in the RET gene. Therapeutic options are limited in recurrent disease but since RET is a tyrosine kinase (TK) receptor involved in cellular growth and proliferation, treatment with a TK-inhibitor might be promising. Several TK-inhibitors have been tested in clinical trials, but it is unknown which inhibitor is most...